Una nuova analisi basata su modelli conferma ulteriormente il potenziale di TECVAYLI®▼ (teclistamab) in associazione con daratumumab nel ridefinire le aspettative di sopravvivenza a lungo termine nel mieloma multiplo recidivante/refrattario trattato in prima linea

Phase 3positiveTECVAYLIdaratumumabPositive

AI Analysis

Summary

Johnson & Johnson announced new Phase 3 MajesTEC-3 data demonstrating that TECVAYLI (teclistamab) in combination with daratumumab achieves durable disease control and survival in relapsed/refractory multiple myeloma patients with 1-3 prior treatment lines.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

MajesTEC-3 Phase 3 study demonstrates durable disease control and survival with teclistamab in combination with daratumumab in relapsed/refractory multiple myeloma patients previously treated with 1-3 prior lines of therapy

Importance:7/10

Sentiment:

0.70

multiple myelomaPhase 3 datacombination therapyoncology

Related Companies

$JNJ

Read the original article

Published by GlobeNewswire Pharma on September 28, 2026 5:58 PM

Read Original